Status:
WITHDRAWN
Lithium and Acetate for Canavan Disease
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborating Sponsors:
European Leukodystrophy Association
Conditions:
Canavan Disease
Infantile
Eligibility:
All Genders
1-15 years
Phase:
PHASE2
Brief Summary
The aim of this study is to determine whether oral supplementation with lithium and acetate may improve the biological and clinical prognosis in patients with Canavan Disease.
Detailed Description
Canavan Disease is an autosomal recessive devastating demyelinating disease caused by a deficiency in Aspartoacylase (ASPA) enzyme. There is no available treatment. ASPA deficiency leads to:- the accu...
Eligibility Criteria
Inclusion
- Clinical and biochemical diagnosis of Canavan disease
Exclusion
- Renal disease
- Thyroid disease
- Cardiac disease
- Impossibility to perform brain MRI
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2011
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00657748
Start Date
September 1 2009
End Date
January 1 2011
Last Update
April 21 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.